Solasia Announces Launch of Darvias® in Japan

Rhea-AI Summary

Solasia Pharma K.K. has announced the launch of its organoarsenic drug, DARVIAS® Injection 135mg (SP-02), in Japan for treating relapsed or refractory Peripheral T-Cell Lymphoma. This drug will be commercialized by Nippon Kayaku Co., Ltd.. The introduction of DARVIAS® represents a significant step in addressing unmet medical needs associated with this challenging condition.

Positive

• Launch of DARVIAS® Injection 135mg in Japan for a specific cancer treatment.
• Collaboration with Nippon Kayaku Co., Ltd. for commercialization.

Negative

• None.

TOKYO--(BUSINESS WIRE)-- Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005303/en/

Solasia Pharma K.K.

Toyokazu Ohata, Public Relations and Investor Relations

Tel: +81 3 5843 8046 (TOKYO)

info@solasia.co.jp

Source: Solasia Pharma K.K.

FAQ

What is DARVIAS® Injection 135mg used for?

DARVIAS® Injection 135mg is used for treating relapsed or refractory Peripheral T-Cell Lymphoma.

Who will commercialize DARVIAS® in Japan?

DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd.

When was DARVIAS® officially launched?

DARVIAS® was officially launched today.

What company is behind DARVIAS® Injection?

DARVIAS® Injection is developed by Solasia Pharma K.K.

What is the stock symbol for Solasia Pharma?

The stock symbol for Solasia Pharma is NPKYY.